Pharma BD Deal Intelligence

Ascidian Therapeutics, Inc. / Exegenesis Bio

2026 · Co-Development · Complete

Ascidian Therapeutics and Exegenesis Bio entered a non-exclusive strategic agreement combining Ascidian's RNA exon editing technology with Exegenesis Bio's AAV capsid engineering and capsid discovery workflows. The companies will evaluate Exegenesis Bio capsids against the delivery requirements of individual RNA exon editing programs, with Ascidian executing resulting exon editor-capsid combinations. Ascidian has partnered and wholly owned programs in retinal, renal, neurological, neuromuscular and genetically defined diseases. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →